Neurosense Therapeutics Ltd is trading at $0.72 (down 5.1%) as the stock undergoes consolidation following a significant price jump earlier this week.
- The recent rally was sparked by news that the company secured a patent in Japan for PrimeC, its lead drug candidate for Amyotrophic Lateral Sclerosis (ALS).
- Today's downward movement appears to be standard profit-taking, as no new company-specific developments have been released since the patent announcement on June 9, 2026.